Modified Self-Amplifying RNA Provides Opportunities For New Vaccines And Treatments [Forbes]
Arcturus Therapeutics Holdings Inc. (ARCT)
Last arcturus therapeutics holdings inc. earnings: 3/11 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.arcturusrx.com/investor-relations
Company Research
Source: Forbes
Research Centers of America on August 07, 2020 in Hollywood, Florida. Research Centers of America is currently conducting COVID-19 vaccine trials, implemented under the federal government's Operation Warp Speed program. The center is recruiting volunteers to participate in the clinical trials, working with the Federal Government and major Pharmaceutical Companies, that are racing to develop a vaccine to potentially prevent COVID-19. (Photo by Joe Raedle/Getty Images) A paper published on July 8, 2024 in the journal presents promising data that offers a foundation for developing future vaccines and treatments. Researchers Joshua McGee, lead author, senior authors Mark Grinstaff, Wilson Wong, and Florian Douam and other colleagues from Boston University solved a longstanding challenge with self-amplifying RNA. They used modified building blocks, called NTPs to build their saRNA. Once they established proof of concept in cells, they tested their method in vaccinated mice against a SARS
Show less
Read more
Impact Snapshot
Event Time:
ARCT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ARCT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ARCT alerts
High impacting Arcturus Therapeutics Holdings Inc. news events
Weekly update
A roundup of the hottest topics
ARCT
News
- Arcturus Therapeutics Receives Clearance of an Investigational New Drug Application to U.S. Food and Drug Administration for ARCT-032, an Investigational Inhaled mRNA Therapeutic to Treat Cystic FibrosisBusiness Wire
- Does Arcturus Therapeutics (ARCT) Have the Potential to Rally 216.35% as Wall Street Analysts Expect? [Yahoo! Finance]Yahoo! Finance
- Arcturus Therapeutics to Attend Upcoming Investor & Scientific ConferencesBusiness Wire
- Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) was upgraded by analysts at Leerink Partnrs to a "strong-buy" rating.MarketBeat
- Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) is now covered by analysts at SVB Leerink LLC. They set an "outperform" rating and a $70.00 price target on the stock.MarketBeat
ARCT
Earnings
- 8/5/24 - Beat
ARCT
Sec Filings
- 8/13/24 - Form 8-K
- 8/5/24 - Form 10-Q
- 8/5/24 - Form 8-K
- ARCT's page on the SEC website